Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.

[1]  P. Gutin,et al.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.

[2]  G. Sonpavde,et al.  Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  T. Nakagawa,et al.  E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models , 2010, Cancer science.

[4]  L. Ellis,et al.  Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology , 2009, Clinical Cancer Research.

[5]  A. Sood,et al.  Combined anti-angiogenic therapy against VEGF and integrin alphabeta in an orthotopic model of ovarian cancer , 2009, Cancer biology & therapy.

[6]  P. Ingham,et al.  Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model , 2009, Proceedings of the National Academy of Sciences.

[7]  P. Keegan,et al.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.

[8]  L. Deangelis,et al.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.

[9]  R. Kalluri,et al.  Drug resistance associated with antiangiogenesis therapy. , 2009, Seminars in cancer biology.

[10]  A. Abdollahi,et al.  Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. , 2009, Blood.

[11]  H. Verheul,et al.  Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[12]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Schmid,et al.  Prostatic Metastasis of Renal Cell Carcinoma Successfully Treated with Sunitinib , 2009, Urologia Internationalis.

[14]  Jeffrey W. Clark,et al.  Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Friess,et al.  Consensus transcriptome signature of perineural invasion in pancreatic carcinoma , 2009, Molecular Cancer Therapeutics.

[16]  G. Melillo,et al.  Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[17]  Y. Meng,et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.

[18]  C. Szczylik,et al.  Sunitinib Malate, a Receptor Tyrosine Kinase Inhibitor, Is Effective in the Treatment of Restrictive Heart Failure due to Heart Metastases from Renal Cell Carcinoma , 2009, Cardiology.

[19]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[20]  R. Kerbel,et al.  Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR , 2009, Proceedings of the National Academy of Sciences.

[21]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[22]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[23]  M. Kost-Alimova,et al.  Horizontal transfer of tumor DNA to endothelial cells in vivo , 2009, Cell Death and Differentiation.

[24]  D. Kuik,et al.  Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib , 2009, Angiogenesis.

[25]  C. Blanke.  Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Seta Shahin,et al.  A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Raychowdhury,et al.  Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. , 2009, Cancer research.

[28]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[29]  R. Kerbel,et al.  Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. , 2009, Cancer cell.

[30]  N. Ferrara,et al.  Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[31]  A. Dudek,et al.  Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. , 2008, European journal of cancer.

[32]  Remy Chait,et al.  Drug interactions modulate the potential for evolution of resistance , 2008, Proceedings of the National Academy of Sciences.

[33]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[34]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[35]  M. Klagsbrun,et al.  Calcification of multipotent prostate tumor endothelium. , 2008, Cancer cell.

[36]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[37]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[38]  H. Gerdes,et al.  Intercellular transfer mediated by tunneling nanotubes. , 2008, Current opinion in cell biology.

[39]  J. Kaiser.  Billion-Dollar Cancer Mapping Project Steps Forward , 2008, Science.

[40]  Dhara N. Amin,et al.  Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. , 2008, Microvascular research.

[41]  A. Abdollahi,et al.  Identification of novel Angiostatin binding partners using a protein array (27K) based high-throughput protein-protein-interaction screen , 2008 .

[42]  H. Rugo,et al.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Debus,et al.  Combination of Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor Inhibition Markedly Improves Radiation Tumor Therapy , 2008, Clinical Cancer Research.

[44]  Rakesh K. Jain,et al.  Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer , 2008, Nature Reviews Cancer.

[45]  N. Normanno,et al.  The role of the EGFR signaling in tumor microenvironment , 2008, Journal of cellular physiology.

[46]  T. Yip,et al.  Platelet-associated PF-4 as a biomarker of early tumor growth. , 2008, Blood.

[47]  D. Nolan,et al.  Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis , 2008, Science.

[48]  F. Peale,et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.

[49]  T. Choueiri,et al.  Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. , 2007, The Journal of urology.

[50]  H. Kalofonos,et al.  Brain metastasis in renal cell cancer responding to sunitinib. , 2007, Anticancer research.

[51]  J. Christensen,et al.  Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy , 2007, Proceedings of the National Academy of Sciences.

[52]  Christopher G Willett,et al.  Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  N. Georgopapadakou,et al.  Anticancer therapeutics: a surge of new developments increasingly target tumor and stroma. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[54]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[55]  Philip Hahnfeldt,et al.  Transcriptional network governing the angiogenic switch in human pancreatic cancer , 2007, Proceedings of the National Academy of Sciences.

[56]  R. Jain,et al.  Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer , 2007, Nature Clinical Practice Oncology.

[57]  R. Kishony,et al.  Antibiotic interactions that select against resistance , 2007, Nature.

[58]  J. Folkman.  Opinion: Angiogenesis: an organizing principle for drug discovery? , 2007, Nature Reviews Drug Discovery.

[59]  Vicky Goh,et al.  Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. , 2007, International journal of radiation oncology, biology, physics.

[60]  V. Pistoia,et al.  Tumor origin of endothelial cells in human neuroblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Michael I Dorrell,et al.  Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis , 2007, Proceedings of the National Academy of Sciences.

[62]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[63]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[64]  G. Semenza,et al.  Regulation of angiogenesis by hypoxia-inducible factor 1. , 2006, Critical reviews in oncology/hematology.

[65]  J. Folkman,et al.  Endostatin therapy reveals a U-shaped curve for antitumor activity , 2006, Cancer Gene Therapy.

[66]  J. Debus,et al.  Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) – phase I/II trial: study protocol , 2006, BMC cancer.

[67]  S. Nill,et al.  Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518) , 2006, BMC Cancer.

[68]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[69]  R. Kishony,et al.  Functional classification of drugs by properties of their pairwise interactions , 2006, Nature Genetics.

[70]  Dhara N. Amin,et al.  Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. , 2006, Cancer research.

[71]  W L Allen,et al.  c-FLIP inhibits chemotherapy-induced colorectal cancer cell death , 2006, Oncogene.

[72]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[73]  O. Sürücü,et al.  Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. , 2005, Cancer research.

[74]  S. Elledge,et al.  An Open Letter to Cancer Researchers , 2005, Science.

[75]  H. Friess,et al.  Randomized phase II – study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer – PARC: study protocol [ISRCTN56652283] , 2005, BMC Cancer.

[76]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[77]  J. Debus,et al.  Inhibition of αvβ3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy , 2005, Clinical Cancer Research.

[78]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[79]  D. Hallahan,et al.  Enhanced radiation damage of tumor vasculature by mTOR inhibitors , 2005, Oncogene.

[80]  M. Westphal,et al.  Inhibition of Glioblastoma Angiogenesis and Invasion by Combined Treatments Directed Against Vascular Endothelial Growth Factor Receptor-2, Epidermal Growth Factor Receptor, and Vascular Endothelial-Cadherin , 2005, Clinical Cancer Research.

[81]  S. Heiland,et al.  Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. , 2005, Cancer research.

[82]  M. Klagsbrun,et al.  A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. , 2005, Cancer research.

[83]  Fabian Kiessling,et al.  Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis , 2005, The Journal of experimental medicine.

[84]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[85]  L. Hlatky,et al.  Endostatin: the logic of antiangiogenic therapy. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[86]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[87]  Dhara N. Amin,et al.  Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities , 2004, Cancer Research.

[88]  J. Debus,et al.  Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. , 2004, International journal of radiation oncology, biology, physics.

[89]  B. Tsang,et al.  Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro , 2004, Oncogene.

[90]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[91]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[92]  J. Rak,et al.  Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand". , 2004, Seminars in cancer biology.

[93]  J. Debus,et al.  Endostatin's antiangiogenic signaling network. , 2004, Molecular cell.

[94]  Hans-Hermann Gerdes,et al.  Nanotubular Highways for Intercellular Organelle Transport , 2004, Science.

[95]  C. Belka,et al.  Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. , 2004, International journal of radiation oncology, biology, physics.

[96]  C. Waldren,et al.  Classical radiation biology dogma, bystander effects and paradigm shifts , 2004, Human & experimental toxicology.

[97]  Philip Hahnfeldt,et al.  Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. , 2003, Cancer research.

[98]  D. Hallahan,et al.  Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response. , 2003, Cancer research.

[99]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[100]  J. Folkman,et al.  Angiogenesis inhibitors and hypoxia , 2003, Nature Medicine.

[101]  Gerald McMahon,et al.  SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. , 2003, Cancer research.

[102]  G. Cesareni,et al.  Glucosylceramide synthase and its functional interaction with RTN-1C regulate chemotherapeutic-induced apoptosis in neuroepithelioma cells. , 2003, Cancer research.

[103]  J. Debus,et al.  SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. , 2003, Cancer research.

[104]  P. Steeg.  Angiogenesis inhibitors: motivators of metastasis? , 2003, Nature Medicine.

[105]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[106]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[107]  P. Hahnfeldt,et al.  Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. , 2003, Journal of theoretical biology.

[108]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[109]  Richard O Hynes,et al.  Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.

[110]  W. Dewey,et al.  Historical and Current Highlights in Radiation Biology: Has Anything Important Been Learned by Irradiating Cells? , 2002, Radiation research.

[111]  D. Hallahan,et al.  Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. , 2002, Cancer research.

[112]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[113]  A. Giaccia,et al.  Antiangiogenic therapy and p53. , 2002, Science.

[114]  M. Sporn,et al.  An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[115]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[116]  D. Hanahan,et al.  VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. , 2002, Cancer cell.

[117]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[118]  E. Ruoslahti.  Specialization of tumour vasculature , 2002, Nature Reviews Cancer.

[119]  Donald W Kufe,et al.  Vascular Endothelial Growth Factor Enhances Endothelial Cell Survival and Tumor Radioresistance , 2002, Cancer journal.

[120]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[121]  C. Ruhrberg,et al.  Endogenous inhibitors of angiogenesis. , 2001, Journal of cell science.

[122]  M. Blagosklonny.  Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). , 2001, International journal of oncology.

[123]  K. Camphausen,et al.  What Does Radiotherapy Do to Endothelial Cells? , 2001, Science.

[124]  Zvi Fuks,et al.  Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice , 2001, Science.

[125]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[126]  Lars Holmgren,et al.  Horizontal transfer of oncogenes by uptake of apoptotic bodies , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[127]  A Rimner,et al.  Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. , 2001, Cancer research.

[128]  K. Camphausen,et al.  Radiation therapy to a primary tumor accelerates metastatic growth in mice. , 2001, Cancer research.

[129]  D. Hallahan,et al.  Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. , 2001, Cancer research.

[130]  Philip Hahnfeldt,et al.  Cancer: looking outside the genome , 2000, Nature Reviews Molecular Cell Biology.

[131]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[132]  Peter Bohlen,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .

[133]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[134]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[135]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[136]  R. Weichselbaum,et al.  Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .

[137]  R. Weichselbaum,et al.  Combined effects of angiostatin and ionizing radiation in antitumour therapy , 1998, Nature.

[138]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[139]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[140]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[141]  J. Folkman.  Clinical Applications of Research on Angiogenesis , 1995 .

[142]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[143]  R. Kerbel,et al.  Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[144]  B. Fertil,et al.  Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. , 1985, International journal of radiation oncology, biology, physics.

[145]  RADIATION RESEARCH SOCIETY , 1975 .

[146]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[147]  Jochen Herms,et al.  Real-time imaging reveals the single steps of brain metastasis formation , 2010, Nature Medicine.

[148]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[149]  J. Debus,et al.  Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[150]  N. Russell,et al.  P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. , 2005, Experimental hematology.

[151]  Y. Kakeji,et al.  Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma , 2004, Breast Cancer Research and Treatment.

[152]  N. Pryer,et al.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model , 2004, Clinical & Experimental Metastasis.

[153]  M. Blagosklonny,et al.  Antiangiogenic therapy and tumor progression. , 2004, Cancer cell.

[154]  T. Kuwana,et al.  Nanotubular Highways for Intercellular Organelle Transport , 2004 .

[155]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. , 2002, Nature medicine.

[156]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins , 2002, Nature Medicine.

[157]  R. Weichselbaum,et al.  Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. , 1999, Cancer research.

[158]  J. Folkman.  Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. , 1995, The New England journal of medicine.

[159]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.